Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av responsen på behandling etter overgang til portleveringssystemet med Ranibizumab [Susvimo ​​(Ranibizumab-injeksjon)] hos pasienter med neovaskulær aldersrelatert makuladegenerasjon tidligere behandlet med andre intravitreale midler enn Ranibizumab (Belvedere)

2. november 2026 oppdatert av: Genentech, Inc.

En fase IV, multisenter, åpen etikett, enarmsstudie av responsen på behandling etter overgang til portleveringssystemet med ranibizumab [Susvimo ​​(Ranibizumab-injeksjon)] hos pasienter med neovaskulær aldersrelatert makuladegenerasjon tidligere behandlet med intravitreale midler Andre Enn Ranibizumab

This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

188

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Arizona
      • Mesa, Arizona, Forente stater, 85206-2747
        • Barnet Dulaney Perkins Eye Center
    • California
      • Bakersfield, California, Forente stater, 93309
        • California Retina Consultants
      • Huntington Beach, California, Forente stater, 92647
        • Retina Associates of Southern California
      • Pasadena, California, Forente stater, 91107-3747
        • California Eye Specialists Medical group Inc.
      • Sacramento, California, Forente stater, 95841-2013
        • Retinal Consultants Med Group
      • San Francisco, California, Forente stater, 94158-2510
        • University of California San Francisco
      • Santa Ana, California, Forente stater, 92705-6504
        • Orange County Retina Med Group
      • Torrance, California, Forente stater, 90503-3270
        • Macula Retina Vitreous Research Institute
    • Colorado
      • Durango, Colorado, Forente stater, 81303
        • Southwest Retina Consultants
      • Longmont, Colorado, Forente stater, 80503-6499
        • Advanced Vision Research Institute
    • Florida
      • Pensacola, Florida, Forente stater, 32503-2030
        • Retina Specialty Institute
      • St. Petersburg, Florida, Forente stater, 33711-1141
        • Retina Vitreous Associates of Florida
    • Georgia
      • Augusta, Georgia, Forente stater, 30909-6440
        • Southeast Retina Center
    • Illinois
      • Lemont, Illinois, Forente stater, 60439-7421
        • University Retina and Macula Associates, PC
    • Maine
      • Portland, Maine, Forente stater, 04101
        • Maine Eye Center
    • Maryland
      • Baltimore, Maryland, Forente stater, 21287-0005
        • Wilmer Eye Institute Johns Hopkins University
      • Baltimore, Maryland, Forente stater, 21209-2219
        • The Retina Care Center
      • Hagerstown, Maryland, Forente stater, 21740
        • Cumberland Valley Retina Consultants PC
    • Michigan
      • Royal Oak, Michigan, Forente stater, 48073
        • Associated Retinal Consultants PC
    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55435-3004
        • VitreoRetinal Surgery, PLLC.
    • Missouri
      • Chesterfield, Missouri, Forente stater, 63017-5065
        • Midwest Vision Research Foundation
    • Nevada
      • Reno, Nevada, Forente stater, 89502-1605
        • Sierra Eye Associates
    • New Jersey
      • Bloomfield, New Jersey, Forente stater, 07003
        • Envision Ocular, LLC
    • New York
      • Poughkeepsie, New York, Forente stater, 12603-2416
        • Seeta Eye Centers
    • North Carolina
      • Durham, North Carolina, Forente stater, 27705-4699
        • Duke Eye Center
      • Hickory, North Carolina, Forente stater, 28602
        • Graystone Eye-Hickory - 2415 Century Pl
    • North Dakota
      • Fargo, North Dakota, Forente stater, 58047
        • Fargo Retina Consultants
    • Ohio
      • Blue Ash, Ohio, Forente stater, 45242-5537
        • Cincinnati Eye Institute
      • Cleveland, Ohio, Forente stater, 44195
        • Cleveland Clinic
    • Pennsylvania
      • Erie, Pennsylvania, Forente stater, 16505
        • Erie Retina Research
    • Tennessee
      • Germantown, Tennessee, Forente stater, 38138-2405
        • Charles Retina Institute
      • Nashville, Tennessee, Forente stater, 37203-1596
        • Tennessee Retina PC
    • Texas
      • Amarillo, Texas, Forente stater, 79106-1835
        • Panhandle Eye Group LLP Southwest Retina Specialists
      • Austin, Texas, Forente stater, 78750-2298
        • Austin Clinical Research, LLC
      • Bellaire, Texas, Forente stater, 77401
        • Retina Consultants of Texas
      • Schertz, Texas, Forente stater, 78154
        • Retina Consultants of Texas
    • Utah
      • Salt Lake City, Utah, Forente stater, 84107-6767
        • Retina Associates of Utah, PLLC
    • Virginia
      • Lynchburg, Virginia, Forente stater, 24502-4271
        • Piedmont Eye Center
      • Norfolk, Virginia, Forente stater, 23502-3933
        • Wagner Kapoor Institute
    • Washington
      • Spokane, Washington, Forente stater, 99204-2509
        • Spokane Eye Clinical Research

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

50 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria

Ocular Inclusion Criteria:

  • Diagnosis of nAMD prior to screening as determined by the investigator

  • Difference of <10% in ECD at screening between the 2 eyes as measured by specular microscopy and determined by the independent reading center

  • Availability of historical visual acuity (VA) data and spectral-domain optical coherence tomography (SD-OCT). Additionally, fluorescein angiography or color fundus photography can both be used to support participant eligibility per protocol at investigator discretion

  • Availability of comprehensive historical anti-vascular endothelial growth factor (VEGF) injection data, including agent administered and date of administration from the time of diagnosis, or for at least 2 years prior to screening if diagnosis was made more than 2 years before screening

  • Response to at least two prior anti-VEGF IVT injections as determined by the investigator based on the following:

    • Overall decrease in nAMD disease activity detected on historical or screening OCT
    • Stable or improved best-corrected visual acuity (BCVA)
  • BCVA of 34 letters (approximate 20/200 Snellen equivalent) or better, using Early Treatment of Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters at screening and enrollment

  • All subtypes of nAMD lesions are permissible

  • nAMD lesions at the time of diagnosis must involve the macula

  • Sufficiently clear ocular media and adequate pupillary dilation to allow for clinical examination and analysis and grading by the central reading center of SD-OCT images

Exclusion Criteria

Prior Ocular Treatment

Study Eye:

  • Prior treatment with external-beam radiation therapy or transpupillary thermotherapy
  • Previous treatment with verteporfin injection (PDT) or corticosteroid IVT injection within 2 years of screening
  • Previous laser (except PDT as stated above) used for age related macular degeneration (AMD) treatment
  • History of corneal transplant
  • History of conjunctival surgery in the superotemporal quadrant
  • History of intraocular inflammation following anti-VEGF injection

Either Eye:

  • Previous PDS implantation
  • Previous intraocular surgery (including cataract surgery) within 6 months of study enrollment
  • Prior vitrectomy surgery, submacular surgery, or other surgical intervention for age-related macular degeneration (AMD)
  • Prior pars plana vitrectomy surgery
  • Previous intraocular device implantation, excluding intraocular lenses
  • History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery
  • Prior participation in a clinical trial involving any intravitreal agents that are not approved at time of screening
  • Intraocular laser therapy, including selective laser trabeculoplasty, yttrium-aluminum garnet (YAG), prophylactic peripheral iridotomy within 1 year of screening, or YAG capsulotomy within 3 months of screening
  • Contact lens wear in either eye within 2 months of screening
  • Any prior penetrating ocular trauma
  • Any prior ocular blunt trauma affecting corneal or retinal health in the opinion of the investigator, or any ocular blunt trauma within 6 months of screening
  • History of corneal transplantation, including partial-thickness corneal grafts
  • Prior treatment with brolucizumab
  • Prior treatment with external-beam radiation therapy or brachytherapy
  • History of hypersensitivity to ranibizumab or any excipients of Susvimo

Macular Neovascularization Lesion (MNV) Characteristics

Study Eye:

  • Subretinal hemorrhage that involves the center of the fovea, if the hemorrhage is greater than 0.5-disc area [1.27 square millimeters (mm^2)] in size
  • Subfoveal fibrosis or subfoveal atrophy

Either Eye:

  • MNV due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia
  • MNV masquerading lesions (e.g., cone dystrophy, adult vitelliform dystrophy, pattern dystrophy)

Current or Historical Ocular Conditions

Study Eye:

  • Retinal pigment epithelial tear
  • Retinal tears or peripheral retinal breaks on depressed fundus exam that are untreated, or treated within the 3 months prior to study enrollment
  • Current vitreous hemorrhage
  • Current or history of retinal detachment
  • Previous violation of the posterior capsule is also an exclusion criterion unless it occurred as a result of YAG laser posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation
  • Spherical equivalent of the refractive error demonstrating more than 8 diopters of myopia or evidence of pathologic myopia on depressed fundus examination
  • Preoperative refractive error that exceeds 8 diopters of myopia, for participants who have undergone prior refractive or cataract surgery
  • Spherical equivalent of the refractive error demonstrating more than 5 diopters of hyperopia
  • Preoperative refractive error that exceeds 5 diopters of hyperopia, for participants who have undergone prior refractive or cataract surgery
  • Uncontrolled ocular hypertension or glaucoma and any such condition the investigator determines may require a glaucoma-filtering surgery during a patient's participation in the study
  • Scleral pathology in the superotemporal quadrant (e.g., scleral thinning or calcification)
  • Conjunctival pathologies in the superotemporal quadrant
  • History or presence of severe posterior blepharitis, recurrent chalazia or hordeolum, severe dry eye syndrome, or severe allergic conjunctivitis
  • Ectropion, entropion or other impairment of the upper or lower eyelid impacting lid functionality needed to protect the ocular surface from exposure
  • Trichiasis
  • Corneal neuropathy
  • Lagophthalmos or incomplete blink
  • Active or history of facial nerve palsy/paresis

Fellow (Non-Study) Eye:

• Concurrent or history of PDS implantation

Either Eye:

  • Aphakia or absence of the posterior capsule
  • Any concurrent intraocular condition that would either require surgical intervention during the study to prevent or treat visual loss that might result from that condition or affect interpretation of study results
  • Corneal ECD ≤1500 cells/mm2 in either eye at screening as determined by the independent reading center
  • Fuchs endothelial corneal dystrophy Grade ≥ 2
  • Previous corneal endothelial cell damage, including from blunt or surgical trauma
  • Any ocular condition that precludes obtaining an analyzable specular microscopy image
  • Active or history of corneal edema
  • Active or history of corneal dystrophies
  • Active or history of iridocorneal endothelial syndrome
  • Active or history of pseudoexfoliation syndrome
  • Active or history of herpetic keratitis or kerato-uveitis
  • Any active or history of uveitis
  • Active intraocular inflammation
  • Active or history of keratitis, scleritis, or endophthalmitis
  • Active ocular or periocular infection
  • Active or history of Sjogren's syndrome or keratoconjunctivitis sicca
  • Active or history of floppy eyelid syndrome
  • Active or history of chronic eye rubbing
  • Active thyroid eye disease

Concurrent Systemic Conditions:

  • History of uncontrolled blood pressure
  • Active or history of autoimmune diseases such as rheumatoid arthritis, lupus, granulomatosis with polyangiitis (Wegener's)
  • History of stroke within the last 3 months prior to screening
  • Uncontrolled atrial fibrillation within 3 months of screening
  • History of myocardial infarction within the last 3 months prior to screening
  • History of other disease, metabolic dysfunction, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab or placement of the implant and that might affect interpretation of the results of the study or renders the patient at high risk of treatment complications, in the opinion of the investigator
  • Current active systemic infection
  • Use of any systemic anti-VEGF agents
  • Chronic use of oral corticosteroids
  • Active cancer within 12 months of enrollment except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of ≤ 6 and a stable prostate-specific antigen for > 12 months
  • Previous participation in any non-ocular (systemic) disease studies of investigational drugs within 1 month prior to screening (excluding vitamins and minerals)
  • Use of antimitotic or antimetabolite therapy within 30 days or 5 elimination half-lives of the screening visit
  • Requirement for continuous use of any medications or treatments indicated as prohibited therapy
  • Pregnant or breastfeeding, or intention to become pregnant during the study
  • Women of childbearing potential must have a negative urine pregnancy test result within 28 days prior to initiation of study treatment. If the urine pregnancy test is positive, it must be confirmed by a serum pregnancy test

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: SUSVIMO

Participants will have the PDS implant (filled prior to implantation with approximately 20 microlitres [uL] of the 100 milligrams/millilitres [mg/ml] formulation of ranibizumab [approximately 2 milligrams (mg) dose of ranibizumab]) surgically inserted in the study eye at the Day 1 visit following their enrollment visit. After the initial fill of the implant with ranibizumab, participants will receive implant refill-exchanges at fixed Q24W intervals.

Ranibizumab 100 mg/mL will be delivered via PDS

Ranibizumab (0.5 mg intravitreal [IVT] injections of 10 mg/mL formulation) will be used in the study eye as supplemental treatment. If a participant discontinues study treatment, he/she may start receiving IVT ranibizumab injections in the study eye, per investigator's discretion.

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Prosentvis endring i korneal endotelcelletetthet (ECD) fra baseline ved uke 48 i studieøyet sammenlignet med det andre øyet, vurdert ved speilmikroskopi
Tidsramme: Baseline, uke 48
Baseline, uke 48

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Prosentvis endring i hornhinne-ECD fra baseline ved uke 24 i studieøyet sammenlignet med det andre øyet
Tidsramme: Baseline, uke 24
Baseline, uke 24
Prosentvis endring i variasjonskoeffisienten (CV) av hornhinneendotelcelleområdet fra baseline ved uke 24 og 48 i studieøyet sammenlignet med det andre øyet
Tidsramme: Baseline, uke 24, uke 48
Baseline, uke 24, uke 48
Prosentvis endring i Hexagonal Cells (HEX) fra baseline ved uke 24 og 48 i studieøyet sammenlignet med det andre øyet
Tidsramme: Baseline, uke 24, uke 48
Baseline, uke 24, uke 48
Prosentandel av deltakere med alvorlige okulære bivirkninger (SAE) og alvorlighetsgraden av SAE
Tidsramme: Dag 1 til ca. uke 52
Dag 1 til ca. uke 52
Prosentandel av deltakere med øyebivirkninger av spesiell interesse (AESI-er) og alvorlighetsgraden av okulære AESI-er
Tidsramme: Dag 1 til uke 52
Dag 1 til uke 52
Varighet av okulær AESI
Tidsramme: Dag 1 til uke 52
Dag 1 til uke 52
Prosentandel av deltakere med okulær AESI i løpet av den postoperative perioden
Tidsramme: Baseline opptil 37 dager etter første implantasjon
Baseline opptil 37 dager etter første implantasjon
Prosentandel av deltakere med okulær AESI i den mellomliggende postoperative perioden
Tidsramme: 38 til 93 dager etter implantasjon
38 til 93 dager etter implantasjon
Prosentandel av deltakere med uønskede enhetseffekter (ADE)
Tidsramme: Dag 1 til uke 52
Dag 1 til uke 52
Antall deltakere med forventede alvorlige uønskede utstyrseffekter (ASADE) og alvorlighetsgraden av ASADE
Tidsramme: Dag 1 til uke 52
Dag 1 til uke 52
Varighet av ASADEs
Tidsramme: Dag 1 til uke 52
Dag 1 til uke 52
Percentage of Participants With Ocular AESIs During the Follow-up Period
Tidsramme: Week 52

The investigator will follow each adverse event (AE) until the event has resolved to baseline grade or better, the event is assessed as stable by the investigator, the participant is lost to follow-up, or the participant withdraws consent.

Week 52

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Clinical Trials, Genentech, Inc.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

14. desember 2021

Primær fullføring (Antatt)

30. juli 2027

Studiet fullført (Antatt)

31. august 2027

Datoer for studieregistrering

Først innsendt

16. april 2021

Først innsendt som oppfylte QC-kriteriene

16. april 2021

Først lagt ut (Faktiske)

21. april 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere